Atypical femur fractures represent a new disease entity associated with the use of oral bisphosphonates. This review summarizes the current understanding of this phenomenon. These fractures are usually transverse, affecting the proximal third of the femoral shaft. They occur after minor or no trauma, include a thickening of the lateral femoral cortex, a delayed consolidation time and prodromal symptoms. In this context, the risk/benefit ratio of bisphosphonates remains favorable if the indication is adequate. In case of fracture, indication to treatment should be reevaluated. Pain or discomfort in the thigh in a patient receiving bisphosphonate should lead to radiological investigations in order to detect the possible occurrence of a stress...
Current evidence suggests that there is an association between bisphosphonate therapy and atypical f...
Comment on Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. [N Engl J Med. ...
In recent years, bisphosphonates and RANK-ligand inhibitors have become the mainstay of treatment fo...
Atypical fractures related to the prolonged use of bisphosphonates are caused by low energy mechanis...
Bisphosphonates (BP) are a commonly prescribed class of drugs for the prevention of osteoporosis-rel...
Increasing numbers of atypical subtrochanteric fractures have been reported among long-term bisphosp...
Osteoporosis is an increasing public health problem. The bisphophonates are the most useful treatmen...
BACKGROUND: Atypical femur fracture is a rare complication of bisphosphonate treatment, which is wid...
Atypical fractures of the femur below the lesser trochanter have been reported in patients treated w...
Background. Atypical femur fractures ( AFFs) present a rare but serious condition associated with us...
Atypical Femoral Fractures (AFF) represent fractures located between the lesser trochanter and the s...
= Abstract = A number of reports regarding atypical fractures of the femur have raised questions con...
Atypical fractures are stress fractures that occur frequently in the femur (subtrochanteric or diaph...
4noAtypical femoral fractures are often associated with prolonged bisphosphonate use. The American ...
Bisphosphonates reduce fractures risk in patients with osteoporosis. A new pattern of fractures is n...
Current evidence suggests that there is an association between bisphosphonate therapy and atypical f...
Comment on Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. [N Engl J Med. ...
In recent years, bisphosphonates and RANK-ligand inhibitors have become the mainstay of treatment fo...
Atypical fractures related to the prolonged use of bisphosphonates are caused by low energy mechanis...
Bisphosphonates (BP) are a commonly prescribed class of drugs for the prevention of osteoporosis-rel...
Increasing numbers of atypical subtrochanteric fractures have been reported among long-term bisphosp...
Osteoporosis is an increasing public health problem. The bisphophonates are the most useful treatmen...
BACKGROUND: Atypical femur fracture is a rare complication of bisphosphonate treatment, which is wid...
Atypical fractures of the femur below the lesser trochanter have been reported in patients treated w...
Background. Atypical femur fractures ( AFFs) present a rare but serious condition associated with us...
Atypical Femoral Fractures (AFF) represent fractures located between the lesser trochanter and the s...
= Abstract = A number of reports regarding atypical fractures of the femur have raised questions con...
Atypical fractures are stress fractures that occur frequently in the femur (subtrochanteric or diaph...
4noAtypical femoral fractures are often associated with prolonged bisphosphonate use. The American ...
Bisphosphonates reduce fractures risk in patients with osteoporosis. A new pattern of fractures is n...
Current evidence suggests that there is an association between bisphosphonate therapy and atypical f...
Comment on Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. [N Engl J Med. ...
In recent years, bisphosphonates and RANK-ligand inhibitors have become the mainstay of treatment fo...